Legal · Compliance
Compliance & regulatory disclosures.
Motark's B2B-only trade posture, no-claims position, jurisdictional limitations, sanctions and AML alignment, and counterparty obligations. Read alongside the operational detail on Operations & Compliance.
Last updated · 19 May 2026
01 · Trade posture
B2B counterparties, written contract, importer of record.
Three baseline principles that apply to every Motark engagement, irrespective of compound or destination.
01
B2B counterparties only
Motark supplies to ingredient distributors, supplement manufacturers, pharmaceutical R&D partners, and other qualified institutional counterparties. We do not sell to individual consumers and do not operate any retail channel.
02
Counterparty verification before any engagement
Before sample shipment, document release, or commercial supply, counterparties are subject to Motark's verification workflow — business email verification, registered organisation lookup, and an intended-use declaration at minimum. Commercial supply additionally requires bank-led KYC and, above thresholds, source-of-funds documentation.
03
Importer of record
The counterparty is the importer of record into the destination jurisdiction and bears responsibility for compliance with applicable import, customs, labelling, registration, and end-product claims requirements. Motark coordinates documentation packages but does not act as importer of record outside Hong Kong.
02 · Jurisdictions
Jurisdictional posture and limitations.
Active markets and the per-jurisdiction notes that govern what we supply, to whom, and under what documentation. Per-compound regulatory status is also surfaced on each compound monograph.
Market
United States
Posture
Compounds with Dietary Supplement use cases are supplied with documentation structured for 21 CFR §111 compliance. NDI notification status varies by compound and is communicated pre-supply.
Market
European Union
Posture
Several compounds in Motark's register carry novel-food classification under Regulation (EU) 2015/2283. Where applicable, novel-food status and any partner-specific authorisation is confirmed before supply.
Market
Australia
Posture
Listed-medicine ingredient framework via the Therapeutic Goods Administration. AUST L documentation packages available on request to verified counterparties.
Market
Hong Kong & ASEAN
Posture
Food-grade extracts supplied per the Centre for Food Safety framework and the harmonised ASEAN traditional medicine framework, adapted to importer-of-record requirements.
Market
Restricted destinations
Posture
Motark will not supply where a destination jurisdiction prohibits the compound, where the counterparty is unable to produce satisfactory documentation, or where a destination requirement (labelling, certification, registration) cannot be met. This applies on a per-compound, per-destination basis.
Market
Excluded compounds
Posture
Motark does not supply Mitragyna speciosa (kratom) or any of its alkaloids (including mitragynine and 7-hydroxymitragynine). Enquiries for these compounds are declined as a matter of policy and are not entered into the workflow.
03 · Claims
No health, therapeutic, or structure/function claims.
Motark's position on what the Site does — and does not — claim about its compounds.
01
No medical or therapeutic claims
Information published on this Site about compounds in Motark's register is technical, regulatory, and commercial reference material for B2B counterparties. Nothing constitutes a claim that any compound diagnoses, treats, cures, mitigates, or prevents any disease, in any jurisdiction.
02
Traditional-use and research context is historical
Where compound monographs reference traditional use or published research, this is for scientific and historical context. It does not constitute, and should not be read as, a nutritional, health, structure/function, or comparable claim about any product made with the compound.
03
Finished-product claims are the counterparty's responsibility
Counterparties who incorporate Motark compounds into finished products are solely responsible for the claims made on those products and for the regulatory pathway in the destination market. Motark does not approve, vet, or warrant counterparty claims.
04 · AML & sanctions
Sanctions, AML, and marketing posture.
Motark operates a counterparty workflow designed in consultation with its banking partners. The full intake procedure — including bank-led KYC, source-of-funds documentation, and the seven-year audit-trail retention — is documented on the Operations & Compliance page; the summary below sets out the position that bears on this legal page.
Sanctions and PEP screening
Commercial supply engagements are routed through Motark's banking partners, who perform sanctions and politically-exposed-person screening (OFAC, UK HMT, EU consolidated, HKMA) as standard banking practice. Where a screening match is identified, the engagement does not proceed.
Jurisdictional sensitivity at intake
Counterparties in jurisdictions with elevated sanctions or AML risk receive additional intake scrutiny. Where the engagement cannot be cleared to the satisfaction of Motark and its banking partners, supply is declined.
No retail or consumer marketing
Motark does not run retail-channel marketing, performance advertising, or consumer-facing campaigns. All outbound communications are addressed to identified B2B counterparties or to the opted-in Motark Updates audience.
Banking enquiries are operational, not investment
The "Banking" enquiry channel on the Contact form is intended for counterparty workflow, AML/KYC documentation, and operational banking questions. It does not constitute an offer of securities, an investment opportunity, or a financial promotion.
05 · Reporting
Reporting concerns.
Three categories of concern we want to hear about, and how to surface them.
01
Compliance concerns
If you believe Motark or one of its partners has acted contrary to applicable regulation or to the posture set out on this page, please email the team. We treat such reports seriously and confidentially.
02
Suspected misuse of Motark identity
If you encounter a third party claiming to act on behalf of Motark — particularly in connection with payment instructions, banking details, or sample shipments — please verify directly with us before acting. We will not change banking details by email without prior signed counterparty notice.
03
Suspected counterparty misuse of supplied compound
Where a Motark-supplied compound is suspected of being diverted, mislabelled, or sold into a channel outside the counterparty contract, please contact the team. Investigations are conducted under NDA.
For institutional reviewers
Diligence pack on request.
Verified counterparties — including banking, audit, and institutional reviewers — can request the full diligence pack covering corporate registration, certifications, AML/KYC workflow, and insurance cover.